Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 747Carcinoma, Renal Cell 237Urinary Bladder Neoplasms 212Carcinoma, Transitional Cell 115Breast Neoplasms 100Kidney Neoplasms 97Neoplasms 91Carcinoma, Non-Small-Cell Lung 86Melanoma 82Ovarian Neoplasms 81Colorectal Neoplasms 76Neoplasm Metastasis 69Non-Muscle Invasive Bladder Neoplasms 58Lung Neoplasms 58Pancreatic Neoplasms 49Endometrial Neoplasms 46Sarcoma 43Stomach Neoplasms 42Uterine Cervical Neoplasms 41Carcinoma, Hepatocellular 36Adenocarcinoma 35Wilms Tumor 33Esophageal Neoplasms 33Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 29Testicular Neoplasms 25Metastatic Castration-resistant Prostate Cancer 25Disease 24Colonic Neoplasms 24

Interventions

darolutamide 2pembrolizumab 1olaparib 1gedatolisib 1enfortumab vedotin 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Gemcitabine 1Fluorouracil 1Cisplatin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Male Urogenital Diseases × Genitourinary × 90 days × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT07103018 2026-03-23

STRIKE-001

K36 Therapeutics, Inc.

Phase 1 Recruiting
144 enrolled
Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡